Abstract
Mortality data were retrieved from the Swedish death registry for the years 1970-2006. This report presents updated information on mortality from Alzheimers disease (AD) through the year 2006, as well as a statistical model of AD mortality with predictive value. This model was developed based on a mortality risk function acting after a specific time point, either step-wise on the whole population or on an increasing part of it. Data collected in recent years indicate that mortality is increasing continuously amongst the oldest patients, while younger age-groups show more stable mortality rates. After fitting the statistical model to age-standardized mortality data it also gave age-specific rates that fit well with reported data without further adjustments in model parameters. The data and the corresponding model for AD mortality suggest that the ability of the body to protect itself from AD-related neurological damage has in general became increasingly impaired since about 1985. This impairment has mainly affected people 65 years of age and older since 1985; the model predicts that in 2020, the age-standardized mortality in Sweden will be 13/100,000 person-years. The author concludes that the increasing mortality is real and not only a result of increasing use of the death classification code for AD.
Keywords: Alzheimer's disease, mortality, mobile phone, blood-brain barrier
Current Alzheimer Research
Title: Is Increased Mortality from Alzheimers Disease in Sweden a Reflection of Better Diagnostics?
Volume: 6 Issue: 6
Author(s): Orjan Hallberg
Affiliation:
Keywords: Alzheimer's disease, mortality, mobile phone, blood-brain barrier
Abstract: Mortality data were retrieved from the Swedish death registry for the years 1970-2006. This report presents updated information on mortality from Alzheimers disease (AD) through the year 2006, as well as a statistical model of AD mortality with predictive value. This model was developed based on a mortality risk function acting after a specific time point, either step-wise on the whole population or on an increasing part of it. Data collected in recent years indicate that mortality is increasing continuously amongst the oldest patients, while younger age-groups show more stable mortality rates. After fitting the statistical model to age-standardized mortality data it also gave age-specific rates that fit well with reported data without further adjustments in model parameters. The data and the corresponding model for AD mortality suggest that the ability of the body to protect itself from AD-related neurological damage has in general became increasingly impaired since about 1985. This impairment has mainly affected people 65 years of age and older since 1985; the model predicts that in 2020, the age-standardized mortality in Sweden will be 13/100,000 person-years. The author concludes that the increasing mortality is real and not only a result of increasing use of the death classification code for AD.
Export Options
About this article
Cite this article as:
Hallberg Orjan, Is Increased Mortality from Alzheimers Disease in Sweden a Reflection of Better Diagnostics?, Current Alzheimer Research 2009; 6 (6) . https://dx.doi.org/10.2174/156720509790147098
DOI https://dx.doi.org/10.2174/156720509790147098 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Strategies Against Prostate Cancer – Pt(II)-Based Chemotherapy
Current Medicinal Chemistry Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?
Current Cancer Drug Targets Recent Progress in Chemically Modified siRNAs
Mini-Reviews in Medicinal Chemistry PDZ Domain Protein-Protein Interactions: A Case Study with PICK1
Current Topics in Medicinal Chemistry Biomedical Applications and Patents on Metallic Nanoparticles
Nanoscience & Nanotechnology-Asia Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme
Current Medicinal Chemistry Thyroid Hormones and their Metabolites: Biological Roles and Association with Non-Alcoholic Fatty Liver Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Phytoestrogen Genistein and Its Pharmacological Interactions with Synthetic Endocrine-Active Compounds
Current Pharmaceutical Design Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype
Current Cancer Drug Targets Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry Superoxide Dismutase in Redox Biology: The Roles of Superoxide and Hydrogen Peroxide
Anti-Cancer Agents in Medicinal Chemistry Receptor Proteins for Nongenomic Actions of Thyroid Hormone
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Is it Possible to Reduce the Incident of Colorectal Cancer by Modifying Diet and Lifestyle?
Current Cancer Therapy Reviews The Role of 18 kDa Mitochondrial Translocator Protein (TSPO) in Programmed Cell Death, and Effects of Steroids on TSPO Expression
Current Molecular Medicine Inhibitors of Steroidal Cytochrome P450 Enzymes as Targets for Drug Development
Recent Patents on Anti-Cancer Drug Discovery New Perspectives in the Treatment of Cushings Syndrome
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Extrapituitary Actions of GnRH Antagonists: Prospects for in vitro Fertilization Programs
Current Pharmaceutical Design